Clinical Trial Update: PF-07104091 as a Single Agent and in Combination Therapy [Phase 2]

View source ↗

Summary

Pfizer's PF-07104091 is being studied as a single agent and in combination therapy in Phase 2 trials for small cell lung cancer, ovarian cancer, and breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Small Cell Lung Cancer

Drugs mentioned

• PF-07104091

Snippet

Sponsor: Pfizer | Conditions: Small Cell Lung Cancer, Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING